SiBone (NASDAQ:SIBN – Get Free Report) and Envista (NYSE:NVST – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.
Volatility and Risk
SiBone has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, Envista has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.
Insider and Institutional Ownership
98.1% of SiBone shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 1.0% of Envista shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares SiBone and Envista’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SiBone | -6.85% | -8.23% | -6.07% |
| Envista | 3.33% | 7.88% | 4.33% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for SiBone and Envista, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SiBone | 1 | 0 | 6 | 0 | 2.71 |
| Envista | 0 | 11 | 6 | 0 | 2.35 |
SiBone presently has a consensus price target of $24.50, suggesting a potential upside of 21.25%. Envista has a consensus price target of $28.86, suggesting a potential upside of 27.15%. Given Envista’s higher probable upside, analysts plainly believe Envista is more favorable than SiBone.
Earnings & Valuation
This table compares SiBone and Envista”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SiBone | $200.93 million | 4.46 | -$18.90 million | ($0.34) | -59.43 |
| Envista | $2.72 billion | 1.34 | $47.00 million | $0.58 | 39.13 |
Envista has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
Summary
Envista beats SiBone on 9 of the 13 factors compared between the two stocks.
About SiBone
SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
